MAPT and early-onset autosomal dominant Alzheimer disease: We suggest that drugs of potential interest for the treatment of Alzheimer's disease should be tested not only on one of the proteins involved in Alzheimer's disease pathology, like amyloid peptide, but also on the component of the other pathological hallmark of Alzheimer's disease, tau protein.